Analysts Set Arvinas, Inc. (NASDAQ:ARVN) Target Price at $60.00

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been assigned an average recommendation of "Buy" from the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. Thirteen analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $60.00.

ARVN has been the subject of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $87.00 price objective on shares of Arvinas in a report on Wednesday, December 11th. Stephens began coverage on shares of Arvinas in a report on Monday, November 18th. They issued an "overweight" rating and a $55.00 target price on the stock. Guggenheim restated a "buy" rating and issued a $57.00 target price on shares of Arvinas in a research note on Wednesday, February 12th. Wedbush reiterated an "outperform" rating and set a $57.00 price target on shares of Arvinas in a research report on Tuesday, February 11th. Finally, Oppenheimer boosted their price objective on Arvinas from $40.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. nVerses Capital LLC acquired a new stake in Arvinas in the third quarter worth about $39,000. KBC Group NV raised its position in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after buying an additional 1,255 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock worth $61,000 after acquiring an additional 440 shares during the period. Quantbot Technologies LP boosted its holdings in shares of Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after acquiring an additional 2,601 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in shares of Arvinas by 37.0% during the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $164,000 after acquiring an additional 1,798 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Price Performance

Shares of NASDAQ:ARVN traded up $1.68 during midday trading on Friday, reaching $19.99. The company had a trading volume of 452,079 shares, compared to its average volume of 896,632. The stock has a market capitalization of $1.37 billion, a P/E ratio of -4.29 and a beta of 1.88. The stock's fifty day moving average price is $18.75 and its 200-day moving average price is $23.10. Arvinas has a one year low of $16.61 and a one year high of $51.99.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. During the same quarter last year, the business earned ($2.53) EPS. As a group, sell-side analysts forecast that Arvinas will post -3.22 earnings per share for the current year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.